Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 14, 2026

Wells Fargo outlines $50B net interest income target for 2026 as balance sheet expansion accelerates

View original at seekingalpha.com
Wells Fargo outlines $50B net interest income target for 2026 as balance sheet expansion accelerates Earnings Call Insights: Wells Fargo & Company (WFC) Q4 2025 MANAGEMENT VIEW * CEO Charles Scharf reported that "net income increased to $21.3 billion and our diluted earnings per share grew 17% from a year ago," attribu…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Noninterest expense expected to be approximately $55.7 billion in 2026

    80% confidence
  • It's too early to know the impact of credit card rate caps because the ultimate actions by administration or Congress are unclear

    80% confidence
  • Wells Fargo earned $5.4 billion in Q4, up 6% from a year ago, with diluted EPS of $1.62, up 13% year-over-year

    80% confidence
  • Wells Fargo advised on two of the largest M&A deals of 2025, increasing announced U.S. M&A ranking to 8th in 2025, up from 12 in 2024

    80% confidence
  • Markets NII expected to grow to approximately $2 billion in 2026 driven by lower short-term funding costs and balance sheet growth

    80% confidence
  • Removal of asset cap and closure of 13 regulatory orders represents a pivotal moment for the company

    80% confidence
  • Wells Fargo doesn't know what the credit environment will be over the next 1, 2, 3, 4, 5 years

    80% confidence
  • Rates coming down will be a headwind for NII ex-markets, but deposit and loan growth should improve results as the year progresses

    80% confidence
  • Office valuations continue to stabilize and although additional losses are expected which can be lumpy, they should be well within expectations

    80% confidence
  • Wells Fargo opened nearly 3 million new credit card accounts in 2025, up 21% from a year ago

    80% confidence
  • Wells Fargo has cut $15 billion of expenses out of the company

    80% confidence
  • Growth in markets business repo trades doesn't attract a lot of capital or RWA

    80% confidence
  • Markets growth is not anticipated to have any negative impact on return on tangible common equity expectations

    80% confidence
  • Net interest income, excluding markets, expected to be approximately $48 billion in 2026

    80% confidence
  • Wells Fargo has significant opportunities to extend loans and use balance sheet for customers and to continue to buy stock back

    80% confidence
  • Total net interest income expected to be $50 billion, plus or minus, in 2026

    80% confidence
  • Net income increased to $21.3 billion and diluted earnings per share grew 17% from a year ago

    80% confidence
  • Assets grew 11% from a year ago including broad-based loan growth and higher trading assets

    80% confidence
  • Wells Fargo increased common stock dividend per share by 13% and repurchased $18 billion of common stock during 2025

    80% confidence
  • Average loans and deposits expected to grow mid-single digits from Q4 2025 to Q4 2026

    80% confidence
  • 2026 guidance assumes 2 to 3 rate cuts by the Federal Reserve with 10-year treasury rates remaining relatively stable

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com
Wells Fargo outlines $50B net interest income target for 2026 as balance sheet expansion accelerates — Source | Via News | ViaNews Market